Growth Inhibition, Tumor Maturation, and Extended Survival in Experimental Brain Tumors in Rats Treated with Phenylacetate

Cancer Research

Volumn 54, Issue 11, 1994, Pages 2923-2927

  Samid, Dvorit ^b   Shack, Sonsoles ^b   Thibault, Alain ^b   Myers, Charles E ^b   Oldfield, Edward H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLACETIC ACID;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DOSE RESPONSE; GLIOSARCOMA; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN NEOPLASMS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOSARCOMA; MICROSCOPY, ELECTRON; NEOPLASM TRANSPLANTATION; PHENYLACETATES; RATS; RATS, INBRED F344; TUMOR STEM CELL ASSAY;

EID: 0028338835     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Samid, D., Shack, S., and Sherman, L.T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-92, 1992.
2. Samid, D., Yeh, A., and Prasanna, P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood, 80: 1576-81, 1992.
3. Samid, D., Shack, S., and Myers, C.E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest., 91: 2288-2295, 1993.
4. Samid, D., Ram, Z., Hudgins, W.R., Shack, S., Liu, L., Walbridge, S., Oldfield, E.H., and Myers, C.E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res., 54: 891-895, 1993.
5. Brusilow, S.W., Danney, M., Waber, L.J., Batshaw, M., Burton, B., Levitsky, L., Roth, K., McKeethren, C., and Ward, J. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N. Engl. J. Med., 310: 1630-1634, 1984.
6. Simell, O., Sipila, I., Rajantie, J., Valle, D.L., and Brusilow, S.W. Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. Pediatr. Res., 20: 1117-1121, 1986.
7. Goldstein, J.L., and Brown, M.S. Regulation of the mevalonate pathway. Nature (Lond.), 343: 425-430, 1990.
8. Marshall, C.J. Protein prenylation: a mediator of protein-protein interactions. Science (Washington DC), 259: 1865-1866, 1993.
9. Burzynski, S.R., Kubove, E., and Burzynski, B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp. Clin. Res., 16: 361-9, 1990.
10. Green, S. Antineoplastons. An unproved cancer therapy. JAMA, 267: 2924-2928, 1992.
11. Weizsaecker, M., Deen, D.F., Rosenblum, M.L., Hoshino, T., Gutin, P.H., and Barker, M. The 9L rat brain tumor: description and application of an animal model. J. Neurol., 224: 183-192, 1981.
12. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
13. Ghadially, F.N. Endoplasmic reticulum and ribosomes in cell differentiation and neoplasia. Ultrastructural Pathology of the Cell and Matrix, pp. 450-454. London: Butterworth, 1992.
14. Porter, K.R. The ground substance: observations from electron microscopy. In: J. Brachet and A.E. Mirsky (eds.), The Cell, p. 621. New York: Academic Press, 1961.
15. Ghadially, F.N. Diagnostic Electron Microscopy of Tumours. London: Butterworth, 1985.
16. Oberling, C.H., and Bernhard, W. The morphology of the cancer cells. In: J. Brachet and A.E. Mirsky (eds.), The Cell, p. 405. New York: Academic Press, 1961.
17. James, M.O., Smith, R.L., Williams, F.R.S., and Reidenberg, M. The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species. Proc. R. Soc. Lond. B Biol., 182: 25-35, 1972.
18. Neish, W.J.P. Phenylacetic acid as a potential therapeutic agent for the treatment of human cancer. Experientia (Basel), 27: 860-861, 1971.